Comprehensive multi-omics analysis showed that CDC6 is a potential prognostic and immunotherapy biomarker for multiple cancer types including HCC

This publication has 67 references indexed in Scilit:

• The cell cycle, cancer development and therapy
  Molecular Biology Reports, 2022
• Sangerbox: A comprehensive, interaction‐friendly clinical bioinformatics analysis platform
  iMeta, 2022
• Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting
  Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2021
• Downregulation of Cdc6 inhibits tumorigenesis of osteosarcoma in vivo and in vitro
  Biomedicine & Pharmacotherapy, 2019
• Epigenetic mechanisms as a new approach in cancer treatment: An updated review
  Genes & Diseases, 2018
• Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation
  Cell, 2018
• Single-Cell RNA Sequencing Reveals T Helper Cells Synthesizing Steroids De Novo to Contribute to Immune Homeostasis
  Cell Reports, 2014
• FOXM1 and androgen receptor co-regulate CDC6 gene transcription and DNA replication in prostate cancer cells
  Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2014
• CD4+ T Cells Regulate Pulmonary Metastasis of Mammary Carcinomas by Enhancing Protumor Properties of Macrophages
  Cancer Cell, 2009
• A novel functional polymorphism in the Cdc6 promoter is associated with the risk for hepatocellular carcinoma
  Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2008